Report Overview

The Global Phenylketonuria drugs market size stood at USD 0.54 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Phenylketonuria (PKU) refers to a genetic disorder and the disease is inherited from parents. The patient suffers from a metabolic defect, in which the body stops being able to break down phenylalanine amino acid that is comprised of protein. Phenylalanine starts getting stored in the blood stream and it damages the brain in consequence

PKU is caused due a defect in the gene which helps to produce phenylalanine hydroxylase. Absence of phenylalanine hydroxylase leads to a buildup of phenylalanine in the body. Timely diagnosis and treatment helps in terminating the symptoms of PKU and avoid brain damage



Market Drivers

The Phenylketonuria Treatment market is anticipated to grow in the forecast, owing to the factors such as increasing research and development of novel drugs, growing acquisitions and collaborations between key market players, approvals of new drugs and growing prevalence of PKU among the children